Comparative Pharmacology
Head-to-head clinical analysis: PSEUDO 12 versus SUDAFED 12 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PSEUDO 12 versus SUDAFED 12 HOUR.
PSEUDO-12 vs SUDAFED 12 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Decongestant; acts on alpha-adrenergic receptors in the nasal mucosa to produce vasoconstriction, reducing edema and nasal congestion.
Pseudoephedrine is a sympathomimetic amine that acts as an agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of nasal mucosa and reducing nasal congestion.
60 mg orally every 4 to 6 hours as needed; maximum 240 mg per day.
120 mg orally every 12 hours, extended-release tablets. Maximum 240 mg per day.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours (adults); 6-8 hours (children); prolonged in renal impairment (up to 20 hours in severe disease).
8-10 hours in adults with normal renal function; prolonged to 19-24 hours in renal impairment (CrCl <30 mL/min); shorter in children (3-4 hours)
Renal: 70-90% as unchanged drug; biliary/fecal: <10%
Renal: 74-95% as unchanged drug; 1-4% as active metabolite (norpsuedoephedrine); biliary/fecal: minimal (<1%)
Category C
Category C
Decongestant
Decongestant